Alonso Sánchez-Cruz

Dr. Alonso Sánchez-Cruz


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ASAlonso Sánchez-Cruz
Alonso Sánchez-Cruz
AMAndrea C. Méndez
Andrea C. Méndez
ILIgnacio Lizasoain
Ignacio Lizasoain
PVPedro de la Villa
Pedro de la Villa
EREnrique J J. de la Rosa
Enrique J J. de la Rosa
CCCATALINA HERNÁNDEZ/ CIB-Margarita CSIC
CATALINA HERNÁNDEZ/ CIB-Margarita CSIC
Although considered a rare retinal dystrophy, retinitis pigmentosa (RP) is the primary cause of hereditary blindness. Given its diverse genetic etiology (>3000 mutations in >60 genes), there is an urgent need for novel treatments that target common features of the disease. TLR2 is a key activator of innate immune response. To examine its role in RP progression we characterized the expression profile of Tlr2 and its adaptor molecules and the consequences of Tlr2 deletion in two genetically distinct models of RP: Pde6brd10/rd10 (rd10) and RhoP23H/+ (P23H/+) mice. In both models, expression levels of Tlr2 and its adaptor molecules increased in parallel with those of the proinflammatory cytokine Il1b. In rd10 mice, deletion of a single Tlr2 allele had no effect on visual function, as evaluated by electroretinography. However, in both RP models, complete elimination of Tlr2 attenuated the loss of visual function and mitigated the loss of photoreceptor cell numbers. In Tlr2 null rd10 mice, we observed decreases in the total number of microglial cells, assessed by flow cytometry, and in the number of microglia infiltrating the photoreceptor layers. Together, these results point to TLR2 as a mutation-independent therapeutic target for RP.

12 May 2022 in Cells
Verified
Journal Article
Open access
PDF file
ASAlonso Sánchez-Cruz
Alonso Sánchez-Cruz
MHMaría Donina Hernández-Fuentes
María Donina Hernández-Fuentes
CMCayetana Murillo-Gómez
Cayetana Murillo-Gómez
EREnrique J J. de la Rosa
Enrique J J. de la Rosa
CCCATALINA HERNÁNDEZ/ CIB-Margarita CSIC
CATALINA HERNÁNDEZ/ CIB-Margarita CSIC
Insulin-degrading enzyme (IDE) was named after its role as a proteolytic enzyme of insulin. However, recent findings suggest that IDE is a widely expressed, multitask protein, with both proteolytic and non-proteolytic functions. Here, we characterize the expression of IDE in the mammalian retina in both physiological and pathological conditions. We found that IDE was enriched in cone inner segments. IDE levels were downregulated in the dystrophic retina of several mouse models of retinitis pigmentosa carrying distinct mutations. In rd10 mice, a commonly studied mouse model of retinitis pigmentosa, treatment with an IDE activator (a synthetic peptide analog of preimplantation factor) delayed loss of visual function and preserved photoreceptor cells. Together, these results point to potential novel roles for IDE in retinal physiology and disease, further extending the list of diverse functions attributed to this enzyme.